Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6934058 | 1.00 | SLC5A2 (0.48) | SLC5A2PYGL | |
| SCHEMBL5482570 | 1.00 | SLC5A2 (0.48) | SLC5A2PYGL | |
| SCHEMBL5483976 | 0.83 | SLC5A2 (0.47) | SLC5A2PYGL | |
| SCHEMBL5486410 | 0.83 | SLC5A2 (0.47) | SLC5A2PYGL | |
| SCHEMBL6788982 | 0.83 | SLC5A2 (0.53) | SLC5A2 | |
| SCHEMBL6789584 | 0.83 | SLC5A2 (0.47) | SLC5A2PYGL | |
| SCHEMBL6786028 | 0.83 | SLC5A2 (0.53) | SLC5A2 | |
| SCHEMBL6789580 | 0.83 | SLC5A2 (0.47) | SLC5A2PYGL | |
| Bromide SCHEMBL8817735 | 0.82 | SLC5A2 (0.46) | SLC5A2PYGL | |
| SCHEMBL6789160 | 0.80 | SLC5A2 (0.46) | SLC5A2PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3903392-B2 | — | — | 2007-04-11 | — | — | JP | claimed |
| US-6248878-B1 | INCLUDING BASES 2-FLUOROPYRIDINE-3-YL, PYRIDINE-2-ONE-3-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-3-YL, 2-BROMOPYRIDINE-5-YL , PYRIDIN-2-ONE-5-YL, 2-AMINOPYRIDINE-5-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-5-YL; ANTISENSE/ANTICANCER AGENTS | RIBOZYME PHARMACEUTICALS, INC. | 2001-06-19 | — | — | US | claimed |
| JP-2001507688-A | — | — | 2001-06-12 | — | — | JP | claimed |
| EP-0948511-A2 | CHEMICAL SYNTHESIS OF NUCLEOSIDES ANALOGS AND THEIR INCORPORATION INTO POLYNUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1998028317-A2 | SYNTHESIS OF NUCLEOSIDES AND POLYNUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-07-02 | — | — | WO | claimed |
| EP-0948511-B1 | CHEMICAL SYNTHESIS OF NUCLEOSIDES ANALOGS AND THEIR INCORPORATION INTO POLYNUCLEOTIDES | SIRNA THERAPEUTICS INC (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | PHARMASSET, INC. | 2004-12-30 | — | — | US | disclosed |
| CN-1527836-A | Antiviral agents for treatment of flaviviridae infections | — | 2004-09-08 | — | — | CN | disclosed |
| US-6248878-B1 | INCLUDING BASES 2-FLUOROPYRIDINE-3-YL, PYRIDINE-2-ONE-3-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-3-YL, 2-BROMOPYRIDINE-5-YL , PYRIDIN-2-ONE-5-YL, 2-AMINOPYRIDINE-5-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-5-YL; ANTISENSE/ANTICANCER AGENTS | RIBOZYME PHARMACEUTICALS, INC. | 2001-06-19 | — | — | US | disclosed |
| US-6248878-B1 | INCLUDING BASES 2-FLUOROPYRIDINE-3-YL, PYRIDINE-2-ONE-3-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-3-YL, 2-BROMOPYRIDINE-5-YL , PYRIDIN-2-ONE-5-YL, 2-AMINOPYRIDINE-5-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-5-YL; ANTISENSE/ANTICANCER AGENTS | RIBOZYME PHARMACEUTICALS, INC. | 2001-06-19 | — | — | US | disclosed |
| EP-0948511-A2 | CHEMICAL SYNTHESIS OF NUCLEOSIDES ANALOGS AND THEIR INCORPORATION INTO POLYNUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998028317-A2 | SYNTHESIS OF NUCLEOSIDES AND POLYNUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | HAVCR2, MAVS, EIF2AK2 | SLC5A2 309/4885PYGL 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.